Literature DB >> 8809676

Signalling pathways mediating secretory and mitogenic responses to galanin and pituitary adenylate cyclase-activating polypeptide in the 235-1 clonal rat lactotroph cell line.

P J Hammond1, D M Smith, K O Akinsanya, W A Mufti, D Wynick, S R Bloom.   

Abstract

The neuropeptides galanin and pituitary adenylate cyclase-activating peptide (PACAP) have been implicated in the physiological regulation of lactotroph function. Using the 235-1 clonal lactotroph rat cell line we have studied the signalling pathways mediating the secretory and mitogenic responses to galanin and PACAP. Both peptides stimulated prolactin release to a similar maximal extent. PACAP (100 nM) stimulated an increase in the proliferation rate of 235-1 cells, but was significantly less effective than 100 nM galanin (161.8 +/- 2.3% vs 296.1 +/- 9.1% of control). PACAP stimulated cAMP accumulation with an ED50 of 3.2 nM, and a maximal effect of almost two-fold at a concentration of 100 nM. Galanin depleted cAMP, by 30% at a concentration of 100 nM. The aminosteroid phospholipase C (PLC) inhibitor U-73122 virtually abolished maximal peptide stimulated prolactin release. Depletion of inositol phosphates or downregulation of protein kinase C reduced maximal peptide stimulated prolactin release from about 260% to about 160% of unstimulated release. Both peptides at a concentration of 100 nM caused a sustained increase in intracellular calcium when incubated with cells for 30 min. These results demonstrate that both peptides stimulate prolactin release and the proliferation rate of 235-1 cells. The most important signalling pathway for prolactin release activated by both peptides is via PLC, although they also regulate cAMP levels, which are increased by PACAP and decreased by galanin. Despite maximal peptide stimulated prolactin release being equal, galanin has a greater mitogenic effect on 235-1 cells than PACAP, raising the possibility that it activates an additional mitogenic signalling pathway.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8809676     DOI: 10.1046/j.1365-2826.1996.04747.x

Source DB:  PubMed          Journal:  J Neuroendocrinol        ISSN: 0953-8194            Impact factor:   3.627


  6 in total

Review 1.  Estrogen action in the regulation of cell proliferation, cell survival, and tumorigenesis in the rat anterior pituitary gland.

Authors:  T J Spady; R D McComb; J D Shull
Journal:  Endocrine       Date:  1999-12       Impact factor: 3.633

2.  Lack of prolactin receptor signaling in mice results in lactotroph proliferation and prolactinomas by dopamine-dependent and -independent mechanisms.

Authors:  Kathryn G Schuff; Shane T Hentges; Michele A Kelly; Nadine Binart; Paul A Kelly; P Michael Iuvone; Sylvia L Asa; Malcolm J Low
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

3.  Galanin regulates prolactin release and lactotroph proliferation.

Authors:  D Wynick; C J Small; A Bacon; F E Holmes; M Norman; C J Ormandy; E Kilic; N C Kerr; M Ghatei; F Talamantes; S R Bloom; V Pachnis
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

4.  Glucocorticoid inhibition of 235-1 rat pituitary tumor cell cycle progression.

Authors:  Beverly C Delidow; Miranda Wang; Sonita V Bhamidipaty; Lynn D Black
Journal:  Endocrine       Date:  2002-03       Impact factor: 3.925

5.  Colorectal cancer patients exhibit increased levels of galanin in serum and colon tissues.

Authors:  Przemysław Kwiatkowski; Janusz Godlewski; Jacek Kieżun; Bartłomiej Emil Kraziński; Zbigniew Kmieć
Journal:  Oncol Lett       Date:  2016-08-23       Impact factor: 2.967

6.  Identification of galanin and its receptor GalR1 as novel determinants of resistance to chemotherapy and potential biomarkers in colorectal cancer.

Authors:  Leanne Stevenson; Wendy L Allen; Richard Turkington; Puthen V Jithesh; Irina Proutski; Gail Stewart; Heinz-Josef Lenz; Sandra Van Schaeybroeck; Daniel B Longley; Patrick G Johnston
Journal:  Clin Cancer Res       Date:  2012-08-02       Impact factor: 12.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.